Form 4: Olema CMO Zojwalla Granted 356,250 Stock Options

Olema Pharmaceuticals' Chief Medical Officer, Naseem Zojwalla, was granted 356,250 stock options, including performance-based awards, on February 2, 2026.

Summary

• Naseem Zojwalla, Chief Medical Officer of Olema Pharmaceuticals, Inc. (OLMA), was granted a total of 356,250 stock options on February 2, 2026.
• This includes 250,000 standard stock options with an exercise price of $25.65, vesting 25% on February 2, 2027, and 1/48th monthly thereafter, subject to continuous service.
• Additionally, 106,250 performance-based stock options were granted with an exercise price of $25.65, eligible to vest based on the Issuer's stock price reaching pre-determined thresholds during two performance periods ending December 31, 2029, and December 31, 2030.
• All options have an expiration date of February 1, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices designed to align management incentives with long-term shareholder value through significant equity grants, including performance-based components.

Positives

• The grant of stock options aligns the Chief Medical Officer's incentives with shareholder value creation, particularly through the performance-based options tied to stock price thresholds.
• The long vesting schedule for standard options (over four years) encourages long-term commitment and retention of a key executive.
• The performance-based options provide a clear incentive for the executive to contribute to significant stock price appreciation.

Negatives

• The issuance of new options could lead to potential dilution for existing shareholders if exercised, although this is standard practice for executive compensation.
• The specific stock price thresholds for performance options are not disclosed, making it difficult to assess the difficulty of achieving these targets.

Future Outlook

The performance-based options indicate a future outlook where the company's stock price is expected to reach certain undisclosed thresholds by December 31, 2029, and December 31, 2030, suggesting management's confidence in future growth and value creation.

Management Comments

• "The undersigned hereby constitutes and appoints each of Amoli Pandya, Sean Bohen and Shawnte Mitchell of Olema Pharmaceuticals, Inc. (the 'Company'), signing individually, the undersigned's true and lawful attorneys-in-fact and agents to: (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the Securities and Exchange Commission (the 'SEC') Forms 3, 4 and 5..." (from Power of Attorney, signed by Naseem Zojwalla)

Industry Context

StockSavvy.ai notes that equity grants, particularly those with performance-based vesting conditions, are a common and effective tool in the biotechnology and pharmaceutical industry to attract, retain, and incentivize key scientific and medical leadership. This grant to the Chief Medical Officer aligns with industry practices aimed at motivating executives to achieve strategic milestones and enhance shareholder value in a highly competitive sector.

Comparison to Industry Standards

• The grant of 356,250 options to a Chief Medical Officer is a substantial equity award, typical for a company in the biotechnology sector where executive compensation often includes significant equity components to align with long-term drug development cycles and potential blockbuster success.
• Comparable companies in the clinical-stage biotech space, such as Mirati Therapeutics (MRTX) or Relay Therapeutics (RLAY), frequently utilize similar multi-year vesting schedules and performance-based equity awards for their C-suite executives to drive innovation and market capitalization growth.
• The inclusion of both time-based and stock price-based performance options reflects a balanced approach to executive incentives, a practice seen across the industry to reward both tenure and achievement of specific financial or operational targets.

Corporate Governance

Related Party Transactions

• The grant of stock options to Naseem Zojwalla, a Chief Medical Officer, constitutes a related party transaction as it involves compensation from the company to an executive.

Stakeholder Impact

• Shareholders: Potential for future dilution upon exercise of options, but also potential for increased shareholder value if the executive's incentives lead to successful company performance and stock price appreciation.
• Employees: May signal confidence in the company's future and its ability to retain key talent.
• Management: Provides significant long-term incentive and compensation for the Chief Medical Officer, aligning their financial interests with the company's success.

Next Steps

• The standard stock options will begin vesting on February 2, 2027, with monthly vesting thereafter.
• The performance-based stock options will be eligible to vest during two distinct performance periods ending December 31, 2029, and December 31, 2030, contingent on the Issuer's stock price reaching pre-determined thresholds.
• The Compensation Committee will certify when price thresholds for performance options are achieved.

Key Dates

Recommendation

The filing reports a routine executive compensation event, specifically the grant of stock options. While the performance-based options align executive incentives with shareholder value, this event alone does not provide sufficient new information to warrant a change in investment thesis. Investors should hold and monitor the company's operational performance and future financial results.

Keywords

Olema Pharmaceuticals, OLMA, Naseem Zojwalla, Chief Medical Officer, Stock Options, Performance Options, Executive Compensation, Insider Trading, SEC Form 4, Equity Grant, Vesting Schedule